ArticleNature biotechnology2020
The global chimeric antigen receptor T (CAR-T) cell therapy patent landscape.
Article in Nature biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Characteristics of Registered Studies of Chimeric Antigen Receptor Therapies: A Systematic Review.JAMA network open · 2021Pooled it
- Exploring the Polyethylene Glycol-Modified Drug Patent Landscape by Deep Learning.Therapeutic innovation & regulatory science · 2026Article
- The global patent landscape of optogenetics: current advances, challenges and opportunities.Nature biotechnology · 2026Article
- Imaging the fate of CAR-T cellsFrontiers in immunology · 2026Review
- Horizon Scanning Methods for Health Care Technology Innovation Identification: Rapid Scoping Review of Patent Research Studies.Interactive journal of medical research · 2025Review
- CAR T-cell immunotherapy as the next horizon in cancer eradication: current landscape, challenges, and future directions.Medical oncology (Northwood, London, England) · 2025Review
- Mapping the patent landscape of TROP2-targeted biologics through deep learning.Nature biotechnology · 2025Article
- Profiling patent compounds in lipid nanoparticle formulations of siRNA.Molecular therapy. Nucleic acids · 2024Article
- Prospects of anti-GD2 immunotherapy for retinoblastoma.Frontiers in immunology · 2024Review
- Charting new paradigms for CAR-T cell therapy beyond current Achilles heels.Frontiers in immunology · 2024Review
- Tri©DB: an integrated platform of knowledgebase and reporting system for cancer precision medicine.Journal of translational medicine · 2023Article
- The global patent landscape of mRNA for diagnosis and therapy.Nature biotechnology · 2023Article
- A new era of macrophage-based cell therapy.Experimental & molecular medicine · 2023Review
- Homology-independent targeted insertion (HITI) enables guided CAR knock-in and efficient clinical scale CAR-T cell manufacturing.Molecular cancer · 2023Article
- The global patent landscape of HER2-targeted biologics.Nature biotechnology · 2023Article
- STING as an emerging therapeutic target for drug discovery: Perspectives from the global patent landscape.Journal of advanced research · 2023Review
- Delivery of therapeutic small interfering RNA: The current patent-based landscape.Molecular therapy. Nucleic acids · 2022Article
- Emerging Novel Combined CAR-T Cell Therapies.Cancers · 2022Review
- A cell-based phenotypic library selection and screening approach for the de novo discovery of novel functional chimeric antigen receptors.Scientific reports · 2022Article
- CAR-based cell therapy: evaluation with bibliometrics and patent analysis.Human vaccines & immunotherapeutics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
33273733What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.